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Abstract
Data on adjuvant therapy in resected nonesmall cell lung cancer (NSCLC) in routine practice are lacking in the
United States. This retrospective observational database study included 609 community oncology patients with
resected stage IB to IIIA NSCLC. Use of adjuvant therapy was 39.1% at disease stage IB and 64.9% to 68.2% at
stage II to IIIA. The most common regimen at all stages was carboplatin and paclitaxel.
Background: Platin-based adjuvant chemotherapy has extended survival in clinical trials in patients with completely
resected nonesmall cell lung cancer (NSCLC). There are few data on the use of adjuvant therapy in community-based
clinical practice in the United States. Materials and Methods: This was a retrospective observational study using
electronic medical record and billing data collected during routine care at US community oncology sites in the Vector
Oncology Data Warehouse between January 2007 and January 2014. Patients aged  18 years with a primary
diagnosis of stage IB to IIIA NSCLC were eligible if they had undergone surgical resection. Treatment patterns, health
care resource use, and cost were recorded, stratiﬁed by stage at diagnosis. Results: The study included 609 patients
(mean age, 64.8 years, 52.9% male), of whom 215 had stage IB disease, 130 stage IIA/II, 110 stage IIB, and 154 stage
IIIA. Adjuvant systemic therapy after resection was provided to 345 (56.7%) of 609 patients, with lower use in patients
with stage IB disease (39.1%) than stage II to IIIA disease (64.9-68.2%) (P < .0001). The most common adjuvant
regimen at all stages was the combination of carboplatin and paclitaxel. There were no statistically signiﬁcant dif-
ferences in ofﬁce visits or incidence of hospitalization by disease stage. During adjuvant treatment, the total monthly
median cost per patient was $17,389.75 (interquartile range, $8,815.61 to $23,360.85). Conclusion: Adjuvant sys-
temic therapy was used in some patients with stage IB NSCLC and in the majority of patients with stage IIA to IIIA
disease. There were few differences in regimen or health care resource use by disease stage.
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Lung cancer is the leading cause of cancer deaths in the United
States (US), with an estimated 159,480 deaths in 2013.1 Approx-
imately 84% of lung cancers are classiﬁed as nonesmall cell lung1GSK, Philadelphia, PA
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Clinical Lung Cancer November 2015cancer (NSCLC).1 The 5-year survival rate across all stages of
NSCLC has been estimated at 16%, increasing to 52% for the 15%
of cases diagnosed at a localized stage.1 Complete surgical resection
is the standard treatment for localized NSCLC.2 Despite complete
resection, the disease recurs in a high proportion of patients.2,3
Adjuvant chemotherapy can help to reduce the risk of recurrence
after surgery and has been investigated in several clinical trials.4-8
Survival beneﬁts have been demonstrated for patients with
completely resected NSCLC receiving adjuvant chemotherapy with
cisplatin-based regimens,4 cisplatin plus vinorelbine,5,6 and carbo-
platin plus paclitaxel in patients with resected stage IB NSCLC with1525-7304/ª 2015 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
http://dx.doi.org/10.1016/j.cllc.2014.12.010
Philip O. Buck et altumors  4 cm in diameter.7 Platin-based adjuvant chemotherapy is
now considered the standard of care in completely resected NSCLC
for patients with good performance status.2
Few studies have investigated the extent to which these clinical
trial ﬁndings have been taken up in routine community-based
clinical practice, and data on treatment patterns are lacking for
the US.
The purpose of the present study was to describe recent treat-
ment patterns and health resource utilization (including cost) for
patients with stage IB to IIIA NSCLC treated in community
oncology practices in the US, who have undergone surgical resection
of their disease. The primary objective was to describe patterns of
systemic treatment (excluding neoadjuvant therapy) by disease stage
at diagnosis. Secondary objectives included describing the clinical
characteristics of patients by stage, disease-free survival, treatment
patterns by starting date of adjuvant treatment from diagnosis (early
compared to late), and health care resource utilization and cost by
disease stage.
Materials and Methods
Study Design
This was a retrospective observational study (GSK study identiﬁer:
HO-13-13748) of treatment patterns, using data collected between
January 2007 and January 2014 as part of routine care for adult pa-
tients with a primary diagnosis of NSCLC in community oncology
settings in the US. Data were obtained from the Vector Oncology
Data Warehouse, which contains electronic medical records and
billing data collected at a network of community oncology practices
mainly in the Southern and Midwestern US.
Study Endpoints
The primary endpoint was treatment pattern by stage at initial
diagnosis. Other endpoints included demographic and clinical
characteristics, disease-free survival, and health care resource use and
cost, stratiﬁed by disease stage at diagnosis.
Patient Population
All potentially eligible patients in the database were screened for
inclusion, and patients who met the eligibility criteria were accrued
in random order until the target number of 600 patients was met.
Patients were drawn from the Vector Oncology Data Warehouse,
and the study sample consisted of those diagnosed with NSCLC
between January 1, 2007, and September 1, 2013.
Eligible patients met the following criteria: conﬁrmed diagnosis
of lung cancer, indicated by a statement in the medical record and
an International Classiﬁcation of Diseases Ninth Revision (ICD-9)
diagnostic code of 162.2 to 162.9; conﬁrmed nonesmall cell dis-
ease type; aged at least 18 years at time of diagnosis; and staged
clinically or pathologically at stage IB to IIIA. In addition, for in-
clusion, patients had to have undergone a qualifying surgical
resection, deﬁned as any surgical resection other than a wedge
resection or segmentectomy for curative treatment of NSCLC as of
the date of data collection. Patients who underwent a qualifying
surgical resection within 30 days after a wedge resection or seg-
mentectomy qualiﬁed for inclusion.
Patients with stage IA disease, or with disease ﬁrst diagnosed at
stage IIIB or IV, were excluded from the study.Data Collection
Patients were initially identiﬁed by Structured Query Language
(SQL) database queries, and eligibility was conﬁrmed through re-
view of medical records by a clinical research nurse. Data were
extracted partly by SQL queries and partly by visual review of re-
cords by clinical research nurses.
The extracted data included: date of birth; date of death; date of
last ofﬁce visit for patients with no recurrence; ethnicity and gender;
date of initial NSCLC diagnosis; date and type of resection; whether
the patient received radiotherapy and/or neoadjuvant therapy (with
the start and end date of radiotherapy if used, and whether radio-
therapy was concurrent with systemic therapy); disease stage (initial
stage if sequential progressive stages were recorded, and pathologic
stage preferred to clinical stage if both were available); details of any
oral, subcutaneous, or intravenous chemotherapy, targeted therapy,
or hormone therapy after resection up to and including the ﬁrst
systemic therapy after disease recurrence or the end of the medical
record, whichever occurred ﬁrst; date and type (local, regional, or
distant) of ﬁrst disease recurrence after resection; biomarker tests for
epidermal growth factor receptor (EGFR), anaplastic lymphoma
kinase (ALK), melanoma-associated antigen 3 (MAGE-A3), Kirsten
rat sarcoma viral oncogene (KRAS), or receptor tyrosine kinase
(ROS1); and billing record data.
The extracted data were used to derive the patient’s age at
diagnosis, treatment regimens used, cost of treatment (directly ob-
tained from the database for injectable therapies, estimated from
unit costs and duration of therapy for oral agents), and duration of
therapy. A treatment regimen was deﬁned as 1 or more anticancer
agents provided over a period of time, provided that all agents
started within 30 days of the start of the ﬁrst agent and that no agent
was discontinued and replaced within 30 days of the start of the ﬁrst
agent. Adjuvant therapy was deﬁned as the ﬁrst systemic therapy
delivered after diagnosis and resection. Therapy after disease
recurrence was deﬁned as the ﬁrst systemic therapy delivered after
the ﬁrst disease recurrence.
The study sample was divided into 3 cohorts on the basis of the
timing of their adjuvant treatment start date relative to their date of
diagnosis: early, late, and no adjuvant therapy administered. The
median time between date of diagnosis and date of start of therapy
for those who were administered adjuvant therapy was used to
divide patients into early versus late treatment initiation.
Data Analysis
Study variables were analyzed using descriptive statistics (eg,
mean, standard deviation [SD], standard error [SE], frequency, and
percentage). The Kaplan-Meier product limit estimator was used to
describe time-to-event outcomes (eg, duration of therapy and
disease-free survival). For time-to-event analyses that included pa-
tients who did not receive systemic therapy, the time origin was the
date of resection. For analyses that included only patients who
received systemic therapy, the time origin was the start of systemic
therapy after diagnosis and resection.
Cost of care included only services delivered through the
oncology practice, including systemic therapy, other drugs, ofﬁce
visits, and other procedures. Costs (except the cost for oral thera-
pies) were taken from the amount charged by the oncology practice
as indicated by the billing system records, inﬂated to 2013 US$Clinical Lung Cancer November 2015 - 487
Table 1 Demographic and Clinical Characteristics of Patients by Disease Stage
Parameter
Disease Stage
P
IB
(n [ 215)
IIA/II
(n [ 130)
IIB
(n [ 110)
IIIA
(n [ 154)
Overall
(n [ 609)
Mean (SD) age at diagnosis, yearsa 65.81 (10.33) 64.22 (9.84) 64.13 (9.69) 64.15 (9.44) 64.75 (9.90) .3005c
No. of subjects with date of diagnosis available 207 123 103 149 582
Gender, n (%) .4054d
Male 108 (50.2%) 65 (50.0%) 65 (59.1%) 84 (54.5%) 322 (52.9%)
Female 107 (49.8%) 65 (50.0%) 45 (40.9%) 70 (45.5%) 287 (47.1%)
Race, n (%) .6274e
White 128 (59.5%) 71 (54.6%) 60 (54.5%) 99 (64.3%) 358 (58.8%)
Black 20 (9.3%) 11 (8.5%) 13 (11.8%) 17 (11.0%) 61 (10.0%)
Asian 2 (0.9%) 1 (0.8%) 1 (0.9%) 2 (1.3%) 6 (1.0%)
Hispanic 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.6%) 2 (0.3%)
Other 2 (0.9%) 2 (1.5%) 1 (0.9%) 0 (0.0%) 5 (0.8%)
Not documented 63 (29.3%) 45 (34.6%) 34 (30.9%) 35 (22.7%) 177 (29.1%)
Region of Patient Residence, n (%) .4639f
Northeast 3 (1.4%) 1 (0.8%) 2 (1.8%) 0 (0.0%) 6 (1.0%)
South 179 (83.3%) 111 (85.4%) 96 (87.3%) 126 (81.8%) 512 (84.1%)
Midwest 33 (15.3%) 18 (13.8%) 12 (10.9%) 28 (18.2%) 91 (14.9%)
Type of Surgical Resection, n (%) .0046e
Bilobectomy 9 (4.2%) 5 (3.8%) 3 (2.7%) 10 (6.5%) 27 (4.4%)
Lobectomy 192 (89.3%) 111 (85.4%) 91 (82.7%) 118 (76.6%) 512 (84.1%)
Pneumonectomy 8 (3.7%) 8 (6.2%) 15 (13.6%) 22 (14.3%) 53 (8.7%)
Sleeve lobectomy 0 (0.0%) 2 (1.5%) 0 (0.0%) 0 (0.0%) 2 (0.3%)
Not speciﬁed 6 (2.8%) 4 (3.1%) 1 (0.9%) 4 (2.6%) 15 (2.5%)
Radiotherapy, n (%) <.0001d
Yes 27 (12.6%) 22 (16.9%) 24 (21.8%) 54 (35.1%) 127 (20.9%)
No 179 (83.3%) 103 (79.2%) 84 (76.4%) 96 (62.3%) 462 (75.9%)
Unknown 9 (4.2%) 5 (3.8%) 2 (1.8%) 4 (2.6%) 20 (3.3%)
Neoadjuvant Therapy, n (%) <.0001f
Yes 6 (2.8%) 7 (5.4%) 13 (11.8%) 38 (24.7%) 64 (10.5%)
No 206 (95.8%) 123 (94.6%) 96 (87.3%) 115 (74.7%) 540 (88.7%)
Unknown 3 (1.4%) 0 (0.0%) 1 (0.9%) 1 (0.6%) 5 (0.8%)
EGFR Testing, n (%) .0897d
Tested 30 (14.0%) 16 (12.3%) 13 (11.8%) 35 (22.7%) 94 (15.4%)
Positiveb 9 (30.0%) 3 (18.8%) 4 (30.8%) 1 (2.9%) 17 (18.1%) .0075f
Negativeb 21 (70.0%) 13 (81.3%) 9 (69.2%) 34 (97.1%) 77 (81.9%)
Not tested 47 (21.9%) 23 (17.7%) 18 (16.4%) 28 (18.2%) 116 (19.0%)
Unknown 138 (64.2%) 91 (70.0%) 79 (71.8%) 91 (59.1%) 399 (65.5%)
Abbreviations: EGFR ¼ epidermal growth factor receptor; SD ¼ standard deviation.
aMean age at diagnosis could not be calculated for some patients due to incomplete data on the date of diagnosis.
bPercentage of patients tested.
cANOVA, under assumption of equal group variances.
dChi-square test.
eMonte Carlo exact test.
fFisher exact test.
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488 -based on the consumer price index for pharmaceuticals and physi-
cian services. Costs for oral therapies were calculated from the drug
name, dose, and start/stop dates in the records, using average
wholesale prices. Costs incurred outside the oncology practice, such
as hospital costs, were not included. Cost and health care resource
use were estimated for 2 time periods: the duration of adjuvantClinical Lung Cancer November 2015therapy, and the time from diagnosis to the end of the initial
regimen after disease recurrence or the end of the medical record,
whichever occurred ﬁrst. To adjust for variable follow-up times
across patients, median monthly costs per patient were calculated on
the basis of the months of follow-up of interest and the costs
accumulated over the period of interest.
Table 2 Systematic Therapy Treatment Patterns by Disease Stage
Regimen
Disease Stage
Overall
(n [ 609)
IB
(n [ 215)
IIA/II
(n [ 130)
IIB
(n [ 110)
IIIA
(n [ 154)
Adjuvant Therapy After Resection, n (%)
Patients receiving adjuvant therapy 84 (39.1%) 86 (66.2%) 75 (68.2%) 100 (64.9%) 345 (56.7%)
Patients receiving second adjuvant therapy 6 (2.8%) 12 (9.2%) 12 (10.9%) 12 (7.8%) 42 (6.9%)
Patients receiving third adjuvant therapy 3 (1.4%) 1 (0.8%) 1 (0.9%) 0 (0.0%) 5 (0.8%)
Adjuvant Therapy, Most Commona First Regimen, n (%)b
Carboplatin 5 (6.0%) 5 (5.8%) 2 (2.7%) 11 (11.0%) 23 (6.7%)
Carboplatin, paclitaxel 25 (29.8%) 21 (24.4%) 23 (30.7%) 34 (34.0%) 103 (29.9%)
Carboplatin, pemetrexed 8 (9.5%) 2 (2.3%) 3 (4.0%) 5 (5.0%) 18 (5.2%)
Cisplatin 9 (10.7%) 15 (17.4%) 9 (12.0%) 15 (15.0%) 48 (13.9%)
Cisplatin, docetaxel 9 (10.7%) 12 (14.0%) 9 (12.0%) 9 (9.0%) 39 (11.3%)
Cisplatin, pemetrexed 7 (8.3%) 9 (10.5%) 5 (6.7%) 4 (4.0%) 25 (7.2%)
Cisplatin, vinorelbine 6 (7.1%) 5 (5.8%) 6 (8.0%) 11 (11.0%) 28 (8.1%)
Other 15 (17.9%) 17 (19.8%) 18 (24.0%) 11 (11.0%) 61 (17.7%)
Adjuvant Therapy, Most Commona Second Regimen, n (%)c
Carboplatin 0 (0.0%) 2 (16.7%) 3 (25.0%) 3 (25.0%) 8 (19.0%)
Carboplatin, docetaxel 0 (0.0%) 3 (25.0%) 1 (8.3%) 0 (0.0%) 4 (9.5%)
Carboplatin, paclitaxel 1 (16.7%) 3 (25.0%) 2 (16.7%) 5 (41.7%) 11 (26.2%)
Carboplatin, pemetrexed 1 (16.7%) 2 (16.7%) 1 (8.3%) 1 (8.3%) 5 (11.9%)
Other 4 (66.7%) 2 (16.7%) 5 (41.7%) 3 (25.0%) 14 (33.3%)
Therapy After Disease Recurrence, n
Patients receiving therapy after disease recurrence 17 15 13 23 68
Therapy After Disease Recurrence, Most Commona Regimen, n (%)d
Bevacizumab, carboplatin, paclitaxel 2 (11.8%) 2 (13.3%) 0 (0.0%) 0 (0.0%) 4 (5.9%)
Carboplatin 1 (5.9%) 0 (0.0%) 1 (7.7%) 4 (17.4%) 6 (8.8%)
Carboplatin, paclitaxel 4 (23.5%) 4 (26.7%) 3 (23.1%) 6 (26.1%) 17 (25.0%)
Carboplatin, pemetrexed 1 (5.9%) 0 (0.0%) 0 (0.0%) 3 (13.0%) 4 (5.9%)
Cisplatin 2 (11.8%) 2 (13.3%) 0 (0.0%) 1 (4.3%) 5 (7.4%)
Erlotinib 3 (17.6%) 1 (6.7%) 1 (7.7%) 2 (8.7%) 7 (10.3%)
Pemetrexed 1 (5.9%) 2 (13.3%) 3 (23.1%) 1 (4.3%) 7 (10.3%)
Other 3 (17.6%) 4 (26.7%) 5 (38.5%) 6 (26.1%) 18 (26.5%)
aReceived by > 5% of patients overall.
bPercentage of patients receiving adjuvant therapy.
cPercentage of patients receiving second adjuvant therapy regimen.
dPercentage of patients receiving therapy after disease recurrence.
Philip O. Buck et alFor analyses inwhich3ormore groupswere compared,P valueswere
from analysis of variance (ANOVA) or a nonparametric Kruskal-Wallis
test for continuous variables and a chi-square test or the Fisher exact test
for categorical variables. In instances where exact computations would
have required a large amount of time and memory, P values were
estimated by Monte Carlo estimation. We used SAS software (SAS
Institute, Cary, NC) to performMonte Carlo estimation by specifying
theMCcomputation option in the EXACT statement of the frequency
procedure. Direct statistical comparisons of cost were not conducted.
Results
Demographic and Clinical Characteristics
A total of 609 patients met all the eligibility criteria and were
included in the ﬁnal analysis. Table 1 shows the demographicand clinical characteristics of the patients, overall and by disease
stage at diagnosis. There were no statistically signiﬁcant differ-
ences in demographics (age, gender, race, region) across the
disease stages. Lobectomy was the most common resection pro-
cedure at all disease stages, although patients with the highest
disease stage (stage IIIA) were less likely to have undergone lo-
bectomy compared to patients with disease at earlier stages (P ¼
.0035). The proportion of patients who received radiotherapy
increased with higher disease stage. Most patients did not receive
neoadjuvant therapy, although it was more commonly provided
to patients with higher disease stage. The only biomarker tested
in more than 10% of patients overall was EGFR, which was
tested for in 15.4% of patients. Overall, 81.9% of patients tested
were EGFR negative.Clinical Lung Cancer November 2015 - 489
Table 3 Health Care Resource Use During Adjuvant Therapy as Well as From Diagnosis to End of First Regimen After Disease
Recurrence or End of Medical Record by Disease Stage
Parameter Disease Stage
PDuring Adjuvant Therapy
IB
(n [ 63)
IIA/II
(n [ 52)
IIB
(n [ 48)
IIIA
(n [ 65)
Overall
(n [ 228)
Ofﬁce Visits
Incidence, n (%) 62 (98.4%) 52 (100.0%) 48 (100.0%) 65 (100.0%) 227 (99.6%) .7149a
Frequency, mean (SD) 11.25 (7.64) 9.15 (4.24) 12.40 (7.71) 12.40 (11.30) 11.34 (8.36) .1461b
Hospitalizations
Incidence, n (%) 12 (19.0%) 3 (5.8%) 7 (14.6%) 13 (20.0%) 35 (15.4%) .1423c
Frequency, mean (SD) 0.38 (0.87) 0.06 (0.24) 0.23 (0.63) 0.31 (0.68) 0.25 (0.67) .0308d
Duration (days), mean (SD) 5.75 (4.56) 3.67 (2.08) 5.57 (4.54) 7.46 (8.82) 6.17 (6.28) .8862e
From Diagnosis to End of First Regimen after
Disease Recurrence or End of Medical Record
IB
(n [ 158)
IIA/II
(n [ 81)
IIB
(n [ 67)
IIIA
(n [ 101)
Overall
(n [ 407) P
Ofﬁce Visits
Incidence, n (%) 151 (95.6%) 77 (95.1%) 64 (95.5%) 92 (91.1%) 384 (94.3%) .4875a
Frequency, mean (SD) 13.29 (15.19) 12.86 (8.91) 17.39 (12.30) 16.54 (15.90) 14.69 (13.97) .0639b
Hospitalizations
Incidence, n (%) 63 (39.9%) 21 (25.9%) 31 (46.3%) 39 (38.6%) 154 (37.8%) .0653c
Frequency, mean (SD) 0.72 (1.08) 0.30 (0.56) 0.73 (0.96) 0.67 (1.03) 0.63 (0.97) .0025d
Duration (days), mean (SD) 6.13 (5.54) 3.38 (2.36) 6.06 (4.71) 7.72 (8.02) 6.14 (5.93) .1280e
Abbreviation: SD ¼ standard deviation.
aFisher exact test.
bANOVA, under assumption of equal group variances.
cChi-square test.
dNegative binomial regression.
eKruskal-Wallis test.
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Table 2 shows the numbers of patients who received adjuvant
chemotherapy and the most commonly used systematic treatment
regimens (deﬁned as those used in > 5% of patients who received
adjuvant therapy). Adjuvant therapy after resection was adminis-
tered to 345 (56.7%) of 609 patients overall. The proportion of
patients receiving adjuvant therapy was lower in patients with the
earliest stage of disease at diagnosis, stage IB (39.1%), compared to
patients at a relatively more advanced stage II to IIIA disease (64.9-
68.2%) (P < .0001).
The most commonly used adjuvant therapy regimen was a com-
bination of carboplatin and paclitaxel, used in 103 (29.9%) of 345
patients. Of the patients who received adjuvant therapy, 42 patients
switched to a second adjuvant regimen, and 5 patients switched to a
third adjuvant regimen (Table 2). The most commonly used second
adjuvant therapy regimen was also carboplatin and paclitaxel; the
number of patients receiving a third adjuvant regimen was too small
to identify the most common regimen.
A total of 68 patients received therapy after disease recurrence,
and the most common regimen was carboplatin and paclitaxel
(Table 2).
Health Care Resource Use and Cost
Billing and charge data during adjuvant treatment were available
for 228 patients. A total of 407 patients had billing and charge data
available at any time. Table 3 presents information on health care
resource use by disease stage during adjuvant treatment and for theClinical Lung Cancer November 2015period from diagnosis up to the end of the ﬁrst regimen after disease
recurrence or end of the medical record (whichever occurred ﬁrst).
There were no statistically signiﬁcant differences across disease
stages in ofﬁce visits, during adjuvant therapy, or from diagnosis to
the end of the ﬁrst regimen after disease recurrence or the end of
medical record, or the incidence or duration of hospitalizations
during adjuvant therapy (Table 3). In contrast, among patients who
experienced recurrence, the frequency of hospitalization differed
signiﬁcantly across groups diagnosed at different stages of disease
(P ¼ .0025), but the duration of hospitalization did not signiﬁ-
cantly differ across groups diagnosed at different stages of disease
(P ¼ .1280).
Table 4 shows cost by disease stage during adjuvant treatment
and for the period of diagnosis up to the end of the ﬁrst regimen
after disease recurrence or end of the medical record (whichever
occurred ﬁrst). During adjuvant treatment, the total monthly me-
dian cost per patient was $17,389.75 (interquartile range,
$8,815.61-23,360.85) whereas the monthly cost from diagnosis
until the end of the initial systemic therapy regimen after recurrence
or the end of medical record was $1,185.08 (interquartile range,
$250.60 to $2,535.99).
The mean overall cost of care during the entire duration of
adjuvant treatment was $49,131.61 (SE $2,359.42). The mean
overall cost from diagnosis until the end of the initial systemic
therapy regimen after recurrence or end of medical record was
$62,986.20 per patient (SE $16,846.85). Overall average costs by
disease stage are shown in Figure 1.
Table 4 Cost of Care Per Month During Adjuvant Therapy as Well as From Diagnosis to the End of First Regimen After Disease Recurrence or End of Medical Record by Disease Stage
Category
Statistic
Cost (US$) by Disease Stage
During Adjuvant Therapy IB (n [ 63) IIA/II (n [ 52) IIB (n [ 48) IIIA (n [ 65) Overallb (n [ 228)
Systemic chemotherapy Median $11,119.87 $13,970.99 $11,422.15 $9,211.14 $11,311.71
IQR $4,921.54-17,014.09 $6,963.59-16,869.85 $5,928.17-16,601.24 $4,075.24-15,641.38 $5,195.70-16,707.72
nc 57 41 38 56 192
Targeted therapy Median $5,099.07 — $7,498.29 — $7,321.16
IQR $5,099.07-5,099.07 — $7,144.02-7,636.08 — $6,121.55-7,567.19
nc 1 0 3 0 4
Infused supportive care drugs Median $4,909.07 $6,275.17 $4,402.89 $5,199.69 $5,338.42
IQR $1,884.89-7,540.52 $4,291.79-8,880.50 $1,676.67-8,877.58 $2,027.30-8,727.50 $2,134.44-8,669.44
nc 30 20 22 25 97
Other drugs Median $1,854.30 $1,949.66 $1,754.20 $1,540.04 $1,795.94
IQR $1,276.21-2,578.76 $1,218.55-2,345.87 $1,153.72-2,563.63 $1,092.75-2,314.66 $1,146.13-2,533.75
nc 58 42 41 57 198
Ofﬁce visits Median $432.41 $362.58 $380.02 $403.50 $403.50
IQR $274.42-588.26 $265.15-509.97 $217.48-614.51 $302.16-553.48 $274.42-574.96
nc 62 52 48 65 227
Other procedure costs Median $2,459.03 $2,060.30 $2,066.88 $2,370.16 $2,213.15
IQR $1,672.99-3,373.25 $1,338.41-2,764.36 $1,457.82-2,942.00 $1,886.47-3,011.05 $1,596.70-3,052.15
nc 62 52 48 65 227
Total costsa Median $17,495.64 $19,178.60 $17,784.05 $13,659.36 $17,389.75
IQR $12,258.13-23,291.50 $6,798.71-22,463.90 $8,152.45-24,341.09 $9,807.96-23,735.01 $8,815.61-23,360.85
n3 63 52 48 65 228
From Diagnosis to End of First Regimen After
Disease Recurrence or End of Medical Record IB (n [ 158) IIA/II (n [ 81) IIB (n [ 67) IIIA (n [ 101) Overall (n [ 407)
Systemic chemotherapy Median $924.33 $1,084.64 $1,034.34 $1,035.61 $1,030.60
IQR $417.53-2,324.48 $770.54-1,648.74 $645.32-1,760.08 $387.40-2,662.71 $475.64-1,865.96
nc 62 43 47 76 228
Targeted therapy Median $2,024.58 $9,651.00 $2,200.31 $1,875.88 $2,275.25
IQR $1,064.78-5,191.78 $9,651.00-9,651.00 $1,691.80-3,486.52 $488.02-3,294.31 $1,064.78-4,447.11
nc 5 1 4 4 14
Infused supportive care drugs Median $652.58 $671.85 $441.28 $422.80 $515.22
IQR $218.59-1,191.98 $396.08-974.85 $257.43-677.28 $271.31-1,135.91 $257.43-1,070.18
nc 35 20 29 29 113
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Overall, approximately three-quarters (75.7%, 461 of 609) of
patients did not have evidence of disease recurrence in their medical
charts. A total of 87 patients had a distant recurrence, and 61 had a
local or regional recurrence. Although there were no statistically
signiﬁcant differences in disease recurrence by disease stage (P ¼
.0908), there appeared to be a trend in which there was a higher
likelihood of disease recurrence, especially distant disease recurrence,
with more advanced stage at diagnosis. In patients who had disease
recurrence, the median time to recurrence was 12.56 months. There
was a trend to shorter time to recurrence with more advanced dis-
ease stage, although this did not reach statistical signiﬁcance (P ¼
.2208) (Table 5).
Kaplan-Meier Analyses
Table 6 shows the results of Kaplan-Meier analyses of the total
duration of adjuvant therapy (all regimens), duration of the initial
regimen after disease recurrence, and disease-free survival by disease
stage. There were no statistically signiﬁcant differences across disease
stages in the duration of adjuvant therapy or the duration of initial
therapy after disease recurrence. There was a difference in disease-
free survival time by disease stage. The log rank test for this anal-
ysis was statistically signiﬁcant (P ¼ .0125), with consistently
shorter median disease-free survival time for patients with more
severe disease at diagnosis compared to earlier disease stages.
Early Versus Late Treatment Start Date
Treatment start dates were recorded for 594 patients (data were
missing for 15 patients [date of diagnosis, 12 patients; date of start
of treatment, 3 patients]). Of these, 165 patients had a record of an
early start date for adjuvant treatment, 168 patients had a late
adjuvant treatment start date, and 261 patients did not receive
adjuvant therapy. There were no signiﬁcant differences between the
groups in terms of gender, race, minority status, or region of resi-
dence (all P > .05). There were statistically signiﬁcant differences
across groups for all of the clinical characteristics measured except
for type of resection (P ¼ .0564).
The most common ﬁrst adjuvant regimen (ie, combined carbo-
platin and paclitaxel) was provided more frequently in patients with
a late treatment start date (32.7%) than in patients with an early
treatment start date (26.1%). Conversely, the second most common
regimen, cisplatin, was provided more frequently in patients with an
early treatment start date (17.6%) than in patients with a late
treatment start date (10.3%).
Discussion
National Comprehensive Cancer Network (NCCN) guidelines
recommend considering adjuvant therapy after surgery for patients
with high-risk stage IB and II NSCLC, and they also recommend
adjuvant systemic chemotherapy for all stage IIIA disease after
surgery.9 Until now, there has been little information available
about the extent to which adjuvant therapy is used in routine
practice by physicians in community oncology practices in the US.
The present study reported that adjuvant therapy was used in
39.1% of patients with stage IB disease at diagnosis, increasing to
approximately two-thirds of patients with stage II to IIIA disease.
The recommended regimens for adjuvant chemotherapy in the
Figure 1 Overall Average Cost of Care Per Patient During Adjuvant Therapy and From Diagnosis to End of First Regimen After Disease
Recurrence or End of Medical Record by Disease Stage
Philip O. Buck et alNCCN guidelines are cisplatin-based, with carboplatin and pacli-
taxel recommended for patients with comorbidities or patients who
cannot tolerate cisplatin.9 Consistent with the most recent guide-
lines, the most common regimens used for adjuvant therapy in this
study were platin-based chemotherapy regimens such as cisplatin,
cisplatin and docetaxel, cisplatin and vinorelbine, and carboplatin
and paclitaxel. There was very little use of newer targeted therapies,
which may reﬂect the patient population, as targeted therapies are
typically used in advanced disease. Few patients were tested for
biomarkers. The only biomarker tested in more than 10% of pa-
tients overall was EGFR, and almost 82% of tested patients were
reported to be EGFR negative.
A study in Canada analyzed data from over 6,000 patients in the
Ontario Cancer Registry who underwent resection for NSCLC to
evaluate the uptake of adjuvant chemotherapy.10 This studyreported an increase in adjuvant chemotherapy use from 7% in
2001-2003 to 31% in 2004-2006.10 The rate of adjuvant therapy
use in the current study was higher than those reported in the
Canadian study, with 56.7% of patients receiving adjuvant therapy
overall. This could be consistent with a continuation of the
increasing trend observed in the Canadian study, because the pre-
sent study was conducted in a later time period (2007-2014), or
could reﬂect country-speciﬁc differences in practice. It could also
reﬂect population differences between the studies; for example, the
Canadian study was conducted in the general population and
the NSCLC stage was unknown in most of the patients, whereas in
the present study the NSCLC stage was precisely deﬁned and the
population was drawn from a network of community oncology
practices. In the Canadian study, 82% of patients with available
information on the drug regimen received cisplatin and 17%Clinical Lung Cancer November 2015 - 493
Table 5 Recurrence of NSCLC After Resection by Disease Stage
Variable/Statistic
Disease Stage
P
IB
(n [ 215)
IIA/II
(n [ 130)
IIB
(n [ 110)
IIIA
(n [ 154)
Overall
(n [ 609)
Recurrence, n (%) .0908a
Yes 43 (20.0%) 29 (22.3%) 28 (25.5%) 48 (31.2%) 148 (24.3%)
No 172 (80.0%) 101 (77.7%) 82 (74.5%) 106 (68.8%) 461 (75.7%)
Overall 215 130 110 154 609
Time to Recurrence, months .2208b
Median 14.33 12.82 11.31 10.68 12.56
Range 3.78-61.64 1.61-62.40 1.94-65.16 0.82-71.54 0.82-71.54
Abbreviation: NSCLC ¼ nonesmall cell lung cancer.
aChi-square test.
bKruskal-Wallis test.
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494 -received carboplatin.10 In the present study, carboplatin use was
higher; almost 30% of patients receiving adjuvant therapy received
carboplatin and paclitaxel.
A study, published in 2013, analyzed data from a community
oncology database in the US on patients with stage I to IV NSCLC
who had started adjuvant or neoadjuvant therapy for early stage
disease, or ﬁrst-line therapy for advanced disease in 2009-2010.11
Consistent with the present study, regimens based on carboplatin
and paclitaxel were the most commonly used.11 Another study inTable 6 Kaplan-Meier Analysis of Duration of Adjuvant Therapy, Du
Disease-Free Survival
Stage Patients Events
Duration of Adjuvant Therapy, months
IB 84 84
IIA/II 86 86
IIB 75 75
IIIA 100 100
Overallb 345 345
Duration of Initial Regimen After Disease
Recurrence, months
IB 17 17
IIA/II 15 15
IIB 13 13
IIIA 23 23
Overall 68 68
Disease-Free Survival Time, monthsc
IB 209 39
IIA/II 128 27
IIB 109 28
IIIA 151 45
Overall 597 139
Abbreviation: CI ¼ conﬁdence interval.
aMedian values are presented for durations. For disease-free survival, instead of the median values, the
uniformly across all stage subgroups.
bConﬁdence interval could not be calculated, likely due to a large number of ties at the median val
cSurvival time could not be calculated for 12 patients as a result of missing date of resection.
Clinical Lung Cancer November 2015the US investigated NSCLC chemotherapy treatment at 8 com-
munity oncology practices, but the majority of patients in this study
had advanced disease (72% stage IIIB to IV),12 so the population
differed substantially from that in the present study.
Our study has a number of limitations. First, it reﬂects treatment
patterns only within community oncology practices that are part of
the Vector Oncology Data Warehouse network, and it is possible
that the Vector Oncology Data Warehouse patient population may
not be representative of the general population of US NSCLCration of Initial Therapy After Disease Recurrence, and
Estimate
(Median/First
Quartile)a
Lower
95% CI
Upper
95% CI
Log Rank
P Value
.5197
2.80 2.80 2.96
2.80 2.80 2.86
2.80 2.80 2.99
2.80 2.76 2.80
2.80 — —
.1523
2.30 1.87 4.18
2.86 1.41 4.64
1.41 0.72 1.87
2.80 1.71 4.14
2.20 1.87 3.26
.0125
42.06 19.83 —
39.13 13.65 —
22.72 13.02 63.12
12.20 7.14 20.45
23.38 17.56 40.32
ﬁrst quartile (75% survival rate) values are reported because the median could not be estimated
ue.
Philip O. Buck et alpatients or of treatment patterns in other practices. For example,
biomarker testing may differ in academic centers compared to
community settings. Second, this was a retrospective study con-
ducted using patient data from 2007 to 2014, and future treatment
patterns may change with the advent of newer treatments in
NSCLC. Third, the cost analysis was based on patient charge data,
which were not available for all the patients in the sample and may
not reﬂect the actual costs incurred. Some costs, such as hospitali-
zations, occurred outside community oncology and thus were not
captured in the study. Fourth, the follow-up time varied between
patients, because the study period extended until the end of the ﬁrst
therapy regimen after disease recurrence or the end of the medical
record, whichever occurred ﬁrst. Fifth, data on some parameters
may not be consistently available from the patient records in
Electronic Medical Record data sources, including those from the
Vector Oncology Data Warehouse.
To our knowledge, this is the ﬁrst study conducted in the US of
community oncology practice patterns in patients with resected
stage IB to IIIA NSCLC. As such, it provides an insight into
treatment patterns and costs in real-world clinical practice. How-
ever, this study only investigated treatment patterns and did not
attempt to compare real-world outcomes such as disease-free and
overall survival between patients with resected NSCLC who
received adjuvant therapy and those who did not receive it. This
would be a potentially interesting area for future research.
Conclusion
In this real-world study of community oncology treatment of
patients with resected NSCLC in the US, adjuvant systemic therapy
was provided in some patients with stage IB NSCLC and in the
majority of patients with stage IIA to IIIA disease. Most patients had
no record of biomarker testing, and targeted therapies were little
used. The most common adjuvant regimens were based on tradi-
tional chemotherapy agents such as carboplatin and cisplatin. There
were few differences in regimen or health care resource use by
disease stage.
Clinical Practice Points
 Complete surgical resection is the standard treatment for early
stage NSCLC; however, disease still recurs in a high proportion
of patients. Adjuvant chemotherapy can help to reduce the risk
of recurrence after surgery and has demonstrated survival beneﬁts
in clinical trials.
 Current NCCN guidelines recommend considering adjuvant
therapy after surgery for patients with high-risk stage IB and II
NSCLC and also recommend adjuvant systemic chemotherapy
for all stage IIIA disease.
 A retrospective observational analysis of electronic medical re-
cords collected during routine care at US community oncology
sites between January 2007 and January 2014 included 609
patients with resected stage IB to IIIA disease; adjuvant systemic
therapy after resection was provided to 56.7% of patients overall,
with signiﬁcantly lower use in patients with stage IB disease
(39.1%) than stage II to IIIA disease (64.9-68.2%).
 The most common adjuvant regimen at all stages was the
combination of carboplatin and paclitaxel. This study providestimely information about the extent to which adjuvant therapy is
used in routine practice by physicians at US community
oncology practices. Adjuvant systemic therapy was used in some
patients with stage IB NSCLC and in a majority of patients with
stage IIA to IIIA disease; the most common therapies utilized
were platin-based chemotherapy regimens.
 Although factors such as performance status, comorbidities, and
patient preference were not directly assessed, these results suggest
that community oncologists in the US are using adjuvant treatment
in a manner consistent with the NCCN guidelines.Acknowledgments
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